Lantern Pharma

$6.09 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Lantern Pharma

Lantern Pharma Inc. is a clinical stage biotechnology company. The Company is focused on developing oncology therapies. It uses its artificial intelligence (AI) platform, RADR, which includes data points, and uses big data analytics to uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that benefits from its compounds. Its portfolio consists of three compounds: LP-100, LP-300 and LP-184. The Company is developing LP-100 for metastatic, castration-resistant, prostate cancer (mCRPC). LP-300 is a small molecule with cysteine modifying activity on select protein. LP-184, is in a preclinical translational ex vivo study using fresh human biopsies. LP-184 is an alkylating agent with nanomolar potency that preferentially damages deoxyribonucleic acid (DNA) in cancer cells that overexpress certain biomarkers.

Stock Analysis

last close $6.09
1-mo return 2.6%
3-mo return 11.5%
avg daily vol. 30.23T
52-week high 14.82
52-week low 4.76
market cap. $59M
forward pe -
annual div. -
roe -19.1%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 30.6%
baraka

Subscribe now for daily local and international financial news

Subscribe